GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin.

TitleGOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin.
Publication TypeJournal Article
Year of Publication2010
JournalCurrent medical research and opinion
Volume26
Issue5
Pagination1055-63
ISSN0300-7995
Abstract

GOAL (Gauging Osteoarthritis [OA] with Limbrel*), an open-label, post-marketing study was performed to determine the overall efficacy and gastrointestinal (GI) tolerability of flavocoxid, a novel, plant-based, anti-inflammatory medication, in a 'real world' clinical practice setting. To this end, the study enrolled several unique patient types including nonsteroidal anti-inflammatory drug (NSAID) naïve patients, those who had used NSAIDs in the past, regardless of outcome (positive or negative), and those who had previously taken a gastroprotective medication to improve GI tolerability or continued to take it as a precautionary measure to prevent NSAID-associated GI damage.

URLhttp://informahealthcare.com/doi/abs/10.1185/03007991003694522
DOI10.1185/03007991003694522
Short TitleCurr Med Res Opin
X
Enter your linkblue username.
Enter your linkblue password.
Secure Login

This login is SSL protected

Loading